Respironics field action

On June 14, 2021, Royal Philips’ subsidiary, Philips Respironics, initiated a voluntary recall notification* for certain sleep and respiratory care products to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices. Following the substantial ramp-up of its production, service, and repair capacity, the repair and replacement program in the U.S. and several other markets is under way. Philips Respironics has also been conducting a comprehensive test and research program on the PE-PUR foam to better assess and scope potential patient health risks related to possible emission of particulates from degraded foam and certain Volatile Organic Compounds (VOCs).

Resolving the recall for patients remains our highest priority

2023

Finalize recall and testing

Manage litigation, DoJ investigation

483 remediation and clarity on proposed Consent Decree

H1 2023

~99% of recall units produced; >4.5M units¹ w/ patients and care providers

Completed all testing and analysis for DS1, DS Go and System One devices

Provision related to anticipated resolution of the economic loss class action in the US

483 remediation in progress

2023-2025

Manage impact of proposed Consent Decree

Manage litigation, DoJ investigation

Gradually restore position

Taking the learnings of Respironics recall to raise Patient Safety and Quality to the highest standards across Philips

1. New replacement devices and repair kits required for the remediation of the total currently registered affected devices.

Test and Research Program
Test and Research Program
Philips Respironics is conducting a comprehensive test and research program to better assess and scope potential patient health risks:

Positive and reassuring test results

Positive and reassuring test results

Positive and reassuring complete test results for DreamStation1 devices

Devices exposed to Ozone

Exposure to VOC emissions unlikely to result in appreciable harm to health

Based on assessment of ozone-induced degradation from up to 500 cleaning cycles

Bioassay evaluation, chemical characterization and toxicological risk assessment (ISO 10993)

Exposure to particulates is unlikely to result in an appreciable harm to health in patients, even based on a worst-case assumption that the patient is exposed to 100% of the foam volume

Particulate Matter testing (ISO 18562-2)

Foam degradation does not contribute to appreciable elevated levels of respirable particles

Exposure to particulate from degraded foam with self-reported ozone use is unlikely to result in an appreciable harm to health in patients

Visual inspection

Foam degradation does not contribute to appreciable elevated levels of respirable particles

Low prevalence of significant visible foam degradation

Ozone cleaning exacerbates foam degradation

July '23: Additional visual inspection confirms low prevalence of significant visible foam degradation/volume reduction - NEW

VOC testing (ISO 18562-3)

Emissions within ISO limits (devices not exposed to ozone)

Positive and reassuring for SystemOne and DreamStation Go

Exposure to foam particulates and VOCs is unlikely to result in an appreciable harm to health in patients, including in devices exposed to Ozone cleaning - NEW

Based on complete, third party:

Risk assessment of foam particulates - Particulate Matter testing (ISO 18562-2)

VOC testing (ISO 18562-3)

Bioassay evaluation, chemical characterization, toxicological risk assessment (ISO 10993)

Philips Respironics has provided the completed set of test results and analyses for the sleep therapy devices to the FDA and other competent authorities. The FDA is still considering the data and analyses that Philips Respironics has provided and may reach different conclusions.

Next steps

Next steps

Complete VOC and Particulate Matter testing, as well as chemical evaluation and toxicological assessments for Trilogy 100/200 (^~3% of registered devices), and OmniLab (^~2% of registered devices)

New Trilogy 100/200 devices passed VOC and PM testing to date, as well as several biocompatibility tests including ISO 10993 cytotoxicity, irritation and sensitization testing

New and lab-aged Trilogy 100/200 foam failed ISO 10993 genotoxicity testing under laboratory conditions, and therefore a weight of evidence assessment is ongoing to confirm or exclude potential risks for patients

These devices contain a different type of PE-PUR foam than the DreamStation1 devices¹

1. The known differences between the DreamStation foam and the foam for the Trilogy 100/200, are that the latter can be used with an acrylic pressure sensitive adhesive, has a lower density, has a different thickness, and also contains an additive to reduce potential flammability.

Summary of third-party epidemiological studies

Summary of third-party epidemiological studies

There were thirteen identified epidemiological studies, all of which found no consistent statistical association between use of PAP devices - including Philips Respironics’- and the risk of cancer in patients with obstructive sleep apnea (OSA) - click here for more details

Two of the studies [1] [2] showed no statistical difference in cancer risk between users of Philips Respironics PAP devices and users of other brands of PAP devices

Eleven studies provided limited additional insights, but their results also suggested no excess risk of cancer associated with use of PAP devices

The 2022 study by Palm and others reported more frequent prescription of respiratory relief medication among patients with both OSA and obstructive lung disease, but no statistical difference in hospitalization, i.e. health outcomes, was observed for OLD among OSA patients between the users or polyurethane PAP and non-foam PAP - click here for more details

[1] An Association between Positive Airway Pressure Device Manufacturer and Incident Cancer? A Secondary Data Analysis; American Journal of Respiratory and Critical Care Medicine, 2021, Volume 204, Issue 12 pp. 1484–1488; Tetyana Kendzerska, Richard S. Leung, Mark I. Boulos, Daniel I. McIsaac, Brian J. Murray, Gregory L. Bryson, Robert Talarico, Atul Malhotra, Andrea S. Gershon, Constance Mackenzie, and Marcus Povitz.

[2] Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea, European Respiratory Journal 2022, in press (https://doi.org/10.1183/13993003.00551-2022), Grégoire Justeau, Chloé Gervès-Pinquié, Marie Jouvenot, Thierry Pigeanne, Sandrine Launois, Laurene Leclair-Visonneau, Philippe Masson, Acya Bizieux-Thaminy, Sébastien Bailly, Nicole Meslier, Abdelkebir Sabil, Jean-Louis Racineux, Wojciech Trzepizur, and Frédéric Gagnadoux.

Please click here for the full testing results and updates
Regulatory and legal update
Regulatory and legal update
Civil litigation

Civil litigation

Collective and individual civil complaints have been filed in various jurisdictions globally, including but not limited to the United States, Australia, Canada, Israel and Chile. The complaints variously allege economic loss, personal injury and, in some cases, the need for medical monitoring

In the United States, putative economic loss and medical monitoring class actions and personal injury lawsuits have been consolidated into a multidistrict litigation (MDL) in Pennsylvania

On September 7, 2023, Philips and certain of its US subsidiaries, including Philips Respironics, reached an agreement to resolve all economic loss claims in the US. The agreement, which provides predefined cash awards to all eligible class members, among other benefits, is awaiting preliminary Court approval

Philips Respironics recorded a provision of EUR 575 million in the first quarter of 2023 to cover the estimated costs of the final settlement. Subject to final Court approval, payments to eligible class members are not expected to begin until Q1 2024 at the earliest. The agreement does not settle any personal injury or medical monitoring claims in the MDL, which the Philips parties have moved to dismiss

As of July 15, 2023, around 600 personal injury claims have been filed and approximately 50,000 individuals had joined the voluntary, court-approved census registry for potential personal injury claimants who have not filed claims but may do so in the future

Visibility on potential outcomes on the medical monitoring class action and personal injury claims is not expected before 2024

SoClean, a manufacturer of ozone-based CPAP cleaning devices, filed an amended complaint against Philips and certain of its US affiliates, including Philips Respironics, in October 2022 for alleged unfair competition, tortious interference with business relationships, defamation and commercial disparagement

Philips believes SoClean’s claims have no basis in fact or law and is seeking dismissal of the case in its entirety, including on the basis that the FDA has stated that CPAP ozone cleaners, like SoClean’s products, “are not legally marketed for this use.”

Securities class action suit was filed against the company in August 2021 in the US, alleging Philips’ statements in connection with the recall triggered a fall in stock price. Plaintiffs filed a Second Amended Complaint in November 2022, which Philips has since moved to dismiss

Given the uncertain nature of the relevant events, and of their potential impact and associated obligations, if any, the company has not provided for these matters other than the anticipated settlement of the economic loss claims in the US

FDA/DOJ

FDA/DOJ

Philips Respironics continues to engage with the US Food and Drug Administration (FDA) on the steps it has taken in response to the FDA’s Form 483 observations

Since July 2022, Philips Respironics has been in discussions with the US Department of Justice (DOJ), acting on behalf of the FDA, regarding the terms of a proposed consent decree to address the identified issues on a forward-going basis

In addition, on April 8, 2022, Philips Respironics and certain of Philips’ subsidiaries in the US received a subpoena from the DOJ to provide information related to events leading to the Philips Respironics recall

Medical Device Reporting

Medical Device Reporting

Medical device manufacturers are required to submit medical device reports (MDRs) to the FDA when they receive complaints for certain types of device malfunctions and safety issues

These complaints may be submitted to the manufacturer by health care professionals, patients, caregivers and consumers

The FDA acknowledges that “the submission of an MDR itself is not evidence that the device caused or contributed to the adverse outcome or event” and that the “cause of an event cannot typically be determined from this reporting system alone.”

Following Philips’ public statements on possible risks to users in April 2021 and the June 2021 recall notification/field safety notice, Philips Respironics received a steep increase in complaints allegedly associated with possible foam degradation

This led to approximately 108,000 MDRs filed by Philips Respironics to the FDA from April 2021 through June 2023

The vast majority (94%) of the MDRs filed since April 2021 up to and including June 2023 are alleged technical malfunctions that do not involve serious injury or death. Based on the investigations to date, Philips Respironics has found no conclusive data linking these devices and the deaths reported in the MDRs
Frequently Asked Questions and key materials

Frequently Asked Questions and key materials

Respironics field action - Progress update - July 24, 2023 (308.0KB)

Respironics field action - FAQ - July 24, 2023 (238.0KB)

Summary of a systematic literature review of PAP device use and cancer risk - July 25, 2022 (182.0KB)

Third party epidemiological studies - FAQ related to the Swedish Study by Palm et al. - July 8, 2022 (201.0KB)

More information

For more information on the recall notification for customers, users and physicians, please click here.

News

You may also find the following articles interesting

Disclaimers

* This is a recall notification for the US only, and a field safety notice for the rest of the world

Respironics field action

Resolving the recall for patients remains our highest priority

2023

H1 2023

2023-2025

Taking the learnings of Respironics recall to raise Patient Safety and Quality to the highest standards across Philips

Philips Respironics is conducting a comprehensive test and research program to better assess and scope potential patient health risks:

More information

News

You may also find the following articles interesting

Philips provides update on completed set of test results for CPAP/BiPAP sleep therapy devices

Philips Respironics provides update on filed MDRs in connection with the voluntary recall notification/field safety notice* for specific CPAP, BiPAP and mechanical ventilator devices

Philips provides update on completed set of test results for first-generation DreamStation sleep therapy devices

Philips Respironics provides update on filed MDRs in connection with the voluntary recall notification/field safety notice* for specific CPAP, BiPAP and mechanical ventilator devices

Philips Respironics update related to Trilogy 100/200 repairs

Summary of a systematic literature review of Positive Airway Pressure device use and cancer risk

Philips provides update on Philips Respironics’ PE-PUR sound abatement foam test and research program

Philips Respironics provides update on filed MDRs in connection with the voluntary recall notification/field safety notice* for specific CPAP, BiPAP and mechanical ventilator devices

Philips Respironics issues voluntary recall notification/field safety notice* for the V60 ventilator product family

Philips Respironics provides update for the US on ongoing CPAP, BiPAP and Mechanical Ventilator field action

Philips provides update on the test and research program in connection with the CPAP, BiPAP and Mechanical Ventilator recall notification*

Philips provides update on earlier announced voluntary CPAP, BiPAP and Mechanical Ventilator recall notification

Philips starts repair and replacement program of first-generation DreamStation devices in the US in relation to earlier announced recall notification

Philips issues recall notification* to mitigate potential health risks related to the sound abatement foam component in certain sleep and respiratory care devices

Contact Investor Relations